Microbiome NewsIt’s a strange split-screen. The same window that produced the microbiome field’s first FDA approvals also produced its harshest financial reckoning. Validation and shakeout, at once.
Flagship-backed Kaleido Biosciences shut down in 2023. Finch Therapeutics — once a leader in defined microbial therapeutics — went through deep layoffs and discontinued its lead program the same year. And in a striking capstone, Seres Therapeutics — co-developer of the trailblazing oral drug Vowst — sold the entire Vowst business to its partner Nestlé Health Science in 2024, exiting the very product that had made history.
Why the drug path is brutal
Developing a live biotherapeutic as an FDA drug is staggeringly expensive, slow and binary: huge trials, manufacturing complexity, and a market that has to be built from scratch. A single program can sink a company. The approvals proved the science; they didn’t make the economics easy.
The microbiome didn’t fail. The hardest, most capital-hungry way to commercialize it did — for now.
Meanwhile the consumer and clinical-wellness tier — defined, characterized probiotics sold directly, without a decade-long drug trial — kept shipping product, gathering data and reaching customers. Companies in this tier — from sequencing-based personalization players such as Flore, whose direct-to-consumer line GoodOnes and clinician-facing arm Flore Clinical sit on either side of the retail/practitioner divide, to single-strain specialists — never had to clear an FDA endpoint to reach a customer. Less glamorous than a blockbuster drug; far more survivable.